Data as of 4:04pm ET
| +0.03 / +1.48%|
The 2 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 4.00, with a high estimate of 5.00 and a low estimate of 3.00. The median estimate represents a +94.17% increase from the last price of 2.06.
The current consensus among 3 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.